1: Ear, Nose and Throat At-A-Glance: Rhinoscopy, Radiology, Nitric Oxide, Rhinomanometry, Endoscopy
1-1JM: Junior Member
1-1JM: Junior Member
Symposium National Symposium 1: KAAACI/KAPARD Symposium - New Insights on Allergy and Asthma: Lessons From Epidemiologic Studies
1-1NAT: Asthma as an Entry Point of Non-Communicable Disease
1-1NAT: Asthma as an Entry Point of Non-Communicable Disease
Workshop 1: Non-Allergic Rhinitis: Current Evidence and Unmet Needs
1-1WS: Classification of Non-Allergic Rhinitis
1-1WS: Classification of Non-Allergic Rhinitis
Workshop 1: Non-Allergic Rhinitis: Current Evidence and Unmet Needs
1-2WS: Does Allergic Rhinitis Affect Communications Skills in Young Adults?
1-2WS: Does Allergic Rhinitis Affect Communications Skills in Young Adults?
Symposium JM Symposium 1: WAO Junior Member Symposium
1-3JSY: International Classification of Diseases (ICD)-11: Are Allergies At Last Going to Be More Visible?
1-3JSY: International Classification of Diseases (ICD)-11: Are Allergies At Last Going to Be More Visible?
New Horizons Session 1: Evidence in Allergen-Specific Immunotherapy
1-3NH: Immunotherapy for Japanese Cedar Pollinosis
1-3NH: Immunotherapy for Japanese Cedar Pollinosis
Workshop 1: Non-Allergic Rhinitis: Current Evidence and Unmet Needs
1-3WS: Update on Pathomechanisms of Eosinophilic Rhinosinusitis
1-3WS: Update on Pathomechanisms of Eosinophilic Rhinosinusitis
Symposium National Symposium 2: KAAACI/KAPARD Symposium - Asthma and Allergic Disease: From Environmental Trigger to Pharmacologic Treatment
2-1NAT: Impact of Particulate Matter on Allergic Diseases in Seoul
2-1NAT: Impact of Particulate Matter on Allergic Diseases in Seoul
Pediatric Track 2: Asthma in Children
2-1PED: Lessons from Cross-Sectional and Longitudinal Studies in Infants and Children
2-1PED: Lessons from Cross-Sectional and Longitudinal Studies in Infants and Children
Symposium National Symposium 2: KAAACI/KAPARD Symposium - Asthma and Allergic Disease: From Environmental Trigger to Pharmacologic Treatment
2-2NAT: The Impact of Inhaled Pollutants on Airway Inflammation
2-2NAT: The Impact of Inhaled Pollutants on Airway Inflammation
APAPARI PG 2: Food Allergy: Diagnostic Approach and Treatment Options
2-2PG: Immunotherapy For Food Allergies: The Prospect For Treatment and Prevention
2-2PG: Immunotherapy For Food Allergies: The Prospect For Treatment and Prevention
Company Sponsored Symposium 2: What We Know About Asthma Treatment
2-3CSS: Who can get the Most Benefit from Tiotropium in Asthma?
2-3CSS: Who can get the Most Benefit from Tiotropium in Asthma?
Sister Society Session 2: European Academy of Allergy and Clinical Immunology (EAACI) Symposium - Precision Medicine: From Molecular Signatures to Predicting Biomarkers
2-3SSS: Phenotypes and Endotypes of Allergic Rhinitis
2-3SSS: Phenotypes and Endotypes of Allergic Rhinitis
Keynote Lecture 3: Albert Oehling Honorary Lecture
3-1KEY: The Identification and Treatment of Patients with Monoclonal Mast Cell Disorders
3-1KEY: The Identification and Treatment of Patients with Monoclonal Mast Cell Disorders
New Horizons Session 3: Biologics in Severe Allergic Diseases
3-1NH: Anti-Cytokines in Severe Asthma
3-1NH: Anti-Cytokines in Severe Asthma
Workshop 3: Recent Update in Chronic Urticaria
3-1WS: Update in the Pathogenesis of Chronic Urticaria in Adults
3-1WS: Update in the Pathogenesis of Chronic Urticaria in Adults
Plenary Session 3: Atopic Dermatitis: From Barrier to Inflammation
3-2PS: Function and Dysfunction of Skin Barrier
3-2PS: Function and Dysfunction of Skin Barrier
Workshop 3: Recent Update in Chronic Urticaria
3-2WS: Natural Course and Etiologic Factors of Chronic Urticaria in Children
3-2WS: Natural Course and Etiologic Factors of Chronic Urticaria in Children
Company Sponsored Symposium 3: Molecular Allergy Diagnostics: Moving Towards Personalized Medicine in Allergy
3-3CSS: Clinical Reactivity vs. Tolerance: Examples from Egg and Milk Allergy
3-3CSS: Clinical Reactivity vs. Tolerance: Examples from Egg and Milk Allergy
Pediatric Track 3: Innovative Approaches in the Management of Asthma
3-3PED: The Novel Mechanism of Probiotics in Allergic Diseases
3-3PED: The Novel Mechanism of Probiotics in Allergic Diseases
APAPARI PG 3: Management and Prevention of Allergic Diseases in Asia
3-3PG: Challenges in the Management of Early Childhood Rhinitis
3-3PG: Challenges in the Management of Early Childhood Rhinitis
Sister Society Session 3: American College of Allergy, Asthma and Immunology (ACAAI) Symposium - Challenges to the Practicing Allergist/Immunologist in the USA
3-3SSS: Choices in Immunotherapy: Sublingual Immunotherapy (SLIT) vs Subcutaneous (SCIT) Immunotherapy
3-3SSS: Choices in Immunotherapy: Sublingual Immunotherapy (SLIT) vs Subcutaneous (SCIT) Immunotherapy
Symposium 3: Advances in the Management of Atopic Dermatitis: A Practical Approach
3-3SY: The Importance of Trigger Avoidance and Vitamin D Substitution
3-3SY: The Importance of Trigger Avoidance and Vitamin D Substitution
Company Sponsored Symposium 3: Molecular Allergy Diagnostics: Moving Towards Personalized Medicine in Allergy
3-4CSS: Food Allergy in Daily Practice: The Emerging Role of MA Diagnostics
3-4CSS: Food Allergy in Daily Practice: The Emerging Role of MA Diagnostics
Pediatric Track 4: Why Don't Pharmacological Agents Work Well in Treatment of Asthma in Very Young Children?
4-1PED: The Pathology of the Airways in Very Young Children with Recurrent Wheeze
4-1PED: The Pathology of the Airways in Very Young Children with Recurrent Wheeze
New Horizons Session 4: Innovative Technology in Allergen Immunotherapy
4-2NH: New Allergen Preparations in Sublingual Immunotherapy (SLIT)
4-2NH: New Allergen Preparations in Sublingual Immunotherapy (SLIT)
Pediatric Track 4: Why Don't Pharmacological Agents Work Well in Treatment of Asthma in Very Young Children?
4-2PED: Review of Efficacy of Current Pharmcological Agents in Very Young Children with Wheeze
4-2PED: Review of Efficacy of Current Pharmcological Agents in Very Young Children with Wheeze
Plenary Session 4: Anaphylaxis through the Life Cycle
4-2PS: Does the Relative Importance of Anaphylaxis Triggers Differ from Infancy to Old Age?
4-2PS: Does the Relative Importance of Anaphylaxis Triggers Differ from Infancy to Old Age?
Sister Society Session 5: Japanese Society of Allergology (JSA) Symposium - Innate Inflammation and Allergic Disease
5-1SSS: Pathogenic Th2 (Tpath2) Cells in Airway Inflammation
5-1SSS: Pathogenic Th2 (Tpath2) Cells in Airway Inflammation
Symposium 5: Recent Advances in Understanding Asthma in the Elderly
5-1SY: Unraveling the Pathways to Asthma Development in the Elderly
5-1SY: Unraveling the Pathways to Asthma Development in the Elderly
Workshop 5: Beyond IgE - Mediated Mechanisms in the Workplace
5-1WS: Baker's Asthma: A Model of Interacting between Innate and Th2 Immune Responses
5-1WS: Baker's Asthma: A Model of Interacting between Innate and Th2 Immune Responses
New Horizons Session 5: Endotypes of Chronic Rhinosinusitis: ICON Session
5-3NH: Developing Eosinophilic Chronic Rhinosinusitis
5-3NH: Developing Eosinophilic Chronic Rhinosinusitis
Sister Society Session 5: Japanese Society of Allergology (JSA) Symposium - Innate Inflammation and Allergic Disease
5-3SSS: Innate Lymphoid Cells in Allergic Inflammation
5-3SSS: Innate Lymphoid Cells in Allergic Inflammation
New Horizons Session 6: Critical Novel Molecules for Allergic Diseases
6-1NH: Role of Thymic Stromal Lymphopoietin (TSLP) in Allergic Responses
6-1NH: Role of Thymic Stromal Lymphopoietin (TSLP) in Allergic Responses
Pediatric Track 6: Environment and Pediatric Allergy
6-1PED: Climate Change, Allergens and Pollinosis
6-1PED: Climate Change, Allergens and Pollinosis
Workshop 6: Patient Education and Adherence in Allergy and Atopic Dermatitis
6-1WS: Anaphylaxis in China
6-1WS: Anaphylaxis in China
Pediatric Track 6: Environment and Pediatric Allergy
6-2PED: Can the Human Microbiome Be Targeted for Therapy of Allergic Disease?
6-2PED: Can the Human Microbiome Be Targeted for Therapy of Allergic Disease?
Sister Society Session 6: Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) Symposium - Important But Neglected Issues in Allergy
6-2SSS: Angioedema without Urticaria
6-2SSS: Angioedema without Urticaria
Symposium 6: Atopic Dermatitis: A Comprehensive Update
6-2SY: Management of Atopic Dermatitis and Emerging Therapies
6-2SY: Management of Atopic Dermatitis and Emerging Therapies
Workshop 6: Patient Education and Adherence in Allergy and Atopic Dermatitis
6-2WS: Education and Adherence in Atopic Dermatitis
6-2WS: Education and Adherence in Atopic Dermatitis
Symposium 6: Atopic Dermatitis: A Comprehensive Update
6-3SY: The Role of Environmental Allergens in the Pathogenesis of Atopic Dermatitis
6-3SY: The Role of Environmental Allergens in the Pathogenesis of Atopic Dermatitis
New Horizons Session 7: Food Immunotherapy: A Global Perspective
7-1NH: Immunotherapy in Food Allergy in Israel
7-1NH: Immunotherapy in Food Allergy in Israel
New Horizons Session 7: Food Immunotherapy: A Global Perspective
7-2NH: Immunotherapy in Food Allergy in Asia
7-2NH: Immunotherapy in Food Allergy in Asia
Workshop 7: Primary Immunodeficiency, Allergy and Inflammation
7-3WS: Profiles of Common Variables in Immunodeficiencies (CVID)
7-3WS: Profiles of Common Variables in Immunodeficiencies (CVID)
Pediatric Track 8: What Have We Learned from Asthma Epidemiology Studies?
8-1PED: Phenotypes of Childhood Asthma
8-1PED: Phenotypes of Childhood Asthma
Workshop 8: Oral Immunotherapy for Pediatric Patients with Food Allergy in Asia
8-1WS: Safety and Feasiblity of Oral Immunotherapy for Food Allergy: Lessons from Asia
8-1WS: Safety and Feasiblity of Oral Immunotherapy for Food Allergy: Lessons from Asia
Sister Society Session 8: Latin American Society of Allergy, Asthma and Immunology (SLaai) - Allergy to Drugs and New Tools and Outcome Measurement
8-2SSS: On-line Registry as a Tool for Describing Drug Hypersensitivities
8-2SSS: On-line Registry as a Tool for Describing Drug Hypersensitivities
New Horizons Session 8: Personalized Medicine: The Way Forward in Allergy and Asthma
8-3NH: The Ethical Framing of Personalized Medicine
8-3NH: The Ethical Framing of Personalized Medicine
Symposium 8: Eosinophil Death Pathways
8-3SY: Eosinophil Biology and Regulation of Eosinophil-Specific Genes
8-3SY: Eosinophil Biology and Regulation of Eosinophil-Specific Genes
New Horizons Session 9: Biomarkers, Biosimilars and Selection of Patients
9-1NH: The Use of Biomarkers in Asthma Clinical Research Trials
9-1NH: The Use of Biomarkers in Asthma Clinical Research Trials
Sister Society Session 9: WISC 2016 Symposium - Advances in the Evaluation and Management of Chronic Urticaria and Angioedema
9-1SSS: Urticaria Guidelines: Consensus and Controversies in the European and American Guidelines
9-1SSS: Urticaria Guidelines: Consensus and Controversies in the European and American Guidelines
Symposium 9: The Most Important Cause of Asthma in Children
9-1SY: A Combination of Genetic and Environmental Factors Is the Most Important Cause of Childhood Asthma
9-1SY: A Combination of Genetic and Environmental Factors Is the Most Important Cause of Childhood Asthma
Workshop 9: Neuro-Immune Interactions in Allergic Airways Diseases
9-1WS: Role of Sensory Neuronal Toll-like Receptors in Itch
9-1WS: Role of Sensory Neuronal Toll-like Receptors in Itch
New Horizons Session 9: Biomarkers, Biosimilars and Selection of Patients
9-2NH: Inner-City Asthma and Anti-IgE
9-2NH: Inner-City Asthma and Anti-IgE
Sister Society Session 9: WISC 2016 Symposium - Advances in the Evaluation and Management of Chronic Urticaria and Angioedema
9-3SSS: Patient Specific Characteristics in the Treatment of Chronic Urticaria: Does it Matter?
9-3SSS: Patient Specific Characteristics in the Treatment of Chronic Urticaria: Does it Matter?
Symposium 9: The Most Important Cause of Asthma in Children
9-3SY: Altered Immune Development Is the Most Important Cause of Childhood Asthma
9-3SY: Altered Immune Development Is the Most Important Cause of Childhood Asthma
New Horizons Session 10: Update in Anaphylaxis: From Infancy to Old Age
10-3NH: Facing Issues of Management of Anaphylaxis
10-3NH: Facing Issues of Management of Anaphylaxis
New Horizons Session 11: The Microbiome and Its Impact on Allergic Disease
11-1NH: The Gut Microbiome on Health and Disease
11-1NH: The Gut Microbiome on Health and Disease
Workshop 11: Improving Adherence in Our Chronic Allergic Patients
11-3WS: What Can We Do to Improve Adherence for Our Patients?
11-3WS: What Can We Do to Improve Adherence for Our Patients?
Workshop 12: Best Evidence and Best Practice for Difficult Cases
12-1WS: Evidence-Based Diagnosis and Management of Severe Pruritus
12-1WS: Evidence-Based Diagnosis and Management of Severe Pruritus
Workshop 12: Best Evidence and Best Practice for Difficult Cases
12-2WS: Updating the Role Played by Immunotherapy for Allergic Rhinitis
12-2WS: Updating the Role Played by Immunotherapy for Allergic Rhinitis
New Horizons Session 13: Environmental Issues and Allergic Diseases
13-1NH: Urban Air Quality and Public Health
13-1NH: Urban Air Quality and Public Health
Symposium 13: Development of Allergy: Lessons from the Birth Cohort Study
13-2SY: The Role of the Microbiome and Hygiene Hypothesis in the Development of Food Allergy
13-2SY: The Role of the Microbiome and Hygiene Hypothesis in the Development of Food Allergy
Workshop 13: Airways Diseases in China
13-2WS: The Current Status of Allergic Diseases in Children in China
13-2WS: The Current Status of Allergic Diseases in Children in China
Workshop 13: Airways Diseases in China
13-3WS: Asthma, Allergy and Environmental Exposure in Chinese Children
13-3WS: Asthma, Allergy and Environmental Exposure in Chinese Children
Symposium 14: Innovative Approaches in Anaphylaxis
14-1SY: Use of Allergen Components: A New Era in Allergology
14-1SY: Use of Allergen Components: A New Era in Allergology
Workshop 14: Exercise-Induced Bronchoconstriction (EIB) and Asthma
14-1WS: Exercise-Induced Bronchoconstriction (EIB) and Asthma (EIA) in the General Population and Asthmatic Subjects
14-1WS: Exercise-Induced Bronchoconstriction (EIB) and Asthma (EIA) in the General Population and Asthmatic Subjects
Symposium 14: Innovative Approaches in Anaphylaxis
14-2SY: Special Considerations on Anaphylaxis in Latin America
14-2SY: Special Considerations on Anaphylaxis in Latin America
Workshop 14: Exercise-Induced Bronchoconstriction (EIB) and Asthma
14-2WS: Indirect Bronchial Challenges to Diagnose Exercise-Induced Bronchoconstriction (EIB)
14-2WS: Indirect Bronchial Challenges to Diagnose Exercise-Induced Bronchoconstriction (EIB)
Symposium 14: Innovative Approaches in Anaphylaxis
14-3SY: Immunologic Intervention of Drug-Induced Anaphylaxis
14-3SY: Immunologic Intervention of Drug-Induced Anaphylaxis
Workshop 14: Exercise-Induced Bronchoconstriction (EIB) and Asthma
14-3WS: Refractoriness during the Repeated Indirect Challenges
14-3WS: Refractoriness during the Repeated Indirect Challenges
Symposium 15: Eosinophils in Asthma and Allergy
15-1SY: Eosinophilia Associated Lung Disease: ABPA, Churg-Strauss Syndrome, and Eosinophilic Pneumonia
15-1SY: Eosinophilia Associated Lung Disease: ABPA, Churg-Strauss Syndrome, and Eosinophilic Pneumonia
Workshop 15: Cough Hypersensitivity Syndrome: A New Approach to Chronic Cough
15-1WS: Evolution of the "Cough Hypersensivity Syndrome" Concept
15-1WS: Evolution of the "Cough Hypersensivity Syndrome" Concept
Workshop 15: Cough Hypersensitivity Syndrome: A New Approach to Chronic Cough
15-2WS: The Differences and Similarities Between Eosinophilic Bronchitis and Asthma
15-2WS: The Differences and Similarities Between Eosinophilic Bronchitis and Asthma
Symposium 15: Eosinophils in Asthma and Allergy
15-3SY: Novel Targeted Therapies for Eosinophilic Disorders
15-3SY: Novel Targeted Therapies for Eosinophilic Disorders
Symposium 16: GLAD-P Symposium - Prevention of Allergy: Is it Possible?
16-2SY: Allergy Strategies Towards Prevention: The GLAD-P Project
16-2SY: Allergy Strategies Towards Prevention: The GLAD-P Project
Workshop 16: New Methodology for Diagnosis of Allergic Disease
16-3WS: Novel Imaging Approach For Asthma
16-3WS: Novel Imaging Approach For Asthma
Symposium 17: Mast Cell in Allergic Inflammation
17-1SY: Mast Cell Regulation of Allergic Inflammation
17-1SY: Mast Cell Regulation of Allergic Inflammation
Workshop 17: Small Airways (SAW) Working Group - Asthma Treatment Issues
17-2WS: New Bronchodilator for Asthma: LAMA and Ultra LABA
17-2WS: New Bronchodilator for Asthma: LAMA and Ultra LABA
Symposium 17: Mast Cell in Allergic Inflammation
17-3SY: Mechanisms of Basophils and Mast Cell Function
17-3SY: Mechanisms of Basophils and Mast Cell Function
Symposium 20: Respiratory Effectiveness Group Symposium: Harnessing the Real World to Address Unmet Needs in Allergy Care
20-1SY: Identifying Obstructive Lung Disease Using Routine Clinical Data: Methods and Real-Life Research Opportunities
20-1SY: Identifying Obstructive Lung Disease Using Routine Clinical Data: Methods and Real-Life Research Opportunities
Symposium 21: Mechanisms in Anaphylaxis: Implications for Clinicians
21-1SY: How Can Drugs as Co-Factors Alter Anaphylaxis?
21-1SY: How Can Drugs as Co-Factors Alter Anaphylaxis?
Symposium 22: Update on the Mechanism of Asthma and Airway Inflammation
22-2SY: Basophil: A Key Player in Immunity and Inflammation
22-2SY: Basophil: A Key Player in Immunity and Inflammation
Symposium 22: Update on the Mechanism of Asthma and Airway Inflammation
22-3SY: Novel Targets for Airway Inflammation: Lessons from Distinct Functions of Subcellular Organelles
22-3SY: Novel Targets for Airway Inflammation: Lessons from Distinct Functions of Subcellular Organelles